The modulation of PCSK-9 and GAGs by 10-dehydrogingerdione and pentoxifylline in hyperlipidemic rabbits

References

• Bernat SI. 2013. Effectiveness of pentoxifylline and of bio-electromagnetic therapy in lower limb obliterative arterial disease. Orvosi Hetilap. 154(42):1674–1679.
   PubMed Web of Science ®Google Scholar
• Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler S, Kleemann R, Bernhagen J, Ihling C. 2002. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation. 105(13):1561–1566.
   PubMed Web of Science ®Google Scholar
• Chang CC, Chang TC, Kao SC, Kuo YF, Chien LF. 1993. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial myxoedema. Acta Endocrinol. 129(4):322–327.
   PubMedGoogle Scholar
• Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, Seidah NG, Prat A. 2012. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 125(7):894–901.
   PubMed Web of Science ®Google Scholar
• El-Seweidy MM, Asker ME-S, Eldahmy SI, Atteia HH, Abdallah MA. 2015. Haemostatic risk factors in dyslipidemic rabbits: role of 10-dehydrogingerdione as a new hypolipemic agent. J Thromb Thrombolysis. 39(2):196–202.
   PubMed Web of Science ®Google Scholar
• Elseweidy MM, Abdallah FR, Younis NN, Aldohmy S, Kassem HM. 2013. 10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits. Atherosclerosis. 231(2):334–340.
   PubMed Web of Science ®Google Scholar
• El-Tantawy WH, Temraz A. 2018. Natural products for controlling hyperlipidemia: review. Arch Physiol Biochem. 19:1–8.
   Google Scholar
• Fatkhullina AR, Peshkova IO, Koltsova EK. 2016. The role of cytokines in the development of atherosclerosis. Biochemistry Mosc. 81(11):1358–1370.
   PubMed Web of Science ®Google Scholar
• Fava C, Montagnana M. 2018. Atherosclerosis is an inflammatory disease which lacks a common anti-inflammatory therapy: How human genetics can help to this issue. A Narrative Review Front Pharmacol. 9:55
   PubMed Web of Science ®Google Scholar
• Fernandes JL, de Oliveira RT, Mamoni RL, Coelho OR, Nicolau JC, Blotta MH, Serrano CV. Jr. 2008. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease-a randomized placebo-controlled study. Atherosclerosis. 196(1):434–442.
   PubMed Web of Science ®Google Scholar
• Gschwandtner M, Strutzmann E, Teixeira MM, Anders HJ, Diedrichs-Mohring M, Gerlza T, Wildner G, Russo RC, Adage T, Kungl AJ. 2017. Glycosaminoglycans are important mediators of neutrophilic inflammation in vivo. Cytokine. 91:65–73.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Giannoukas AD, Athyros VG, Mikhailidis DP. 2018. Lipid-lowering treatment in peripheral artery disease. Curr Opin Pharmacol. 39:19–26.
   PubMed Web of Science ®Google Scholar
• Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ. 2015. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol. 115(2):178–182.
   PubMed Web of Science ®Google Scholar
• Landlinger C, Pouwer MG, Juno C, van der Hoorn JWA, Pieterman EJ, Jukema JW, Staffler G, Princen HMG, Galabova G. 2017. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J. 38(32):2499–2507.
   PubMed Web of Science ®Google Scholar
• Madhumathi BG, Venkataranganna MV, Gopumadhavan S, Rafiq M, Mitra SK. 2006. Induction and evaluation of atherosclerosis in New Zealand white rabbits. Indian J Exp Biol. 44(3):203–208.
   PubMedGoogle Scholar
• McCarty MF, O'Keefe JH, DiNicolantonio JJ. 2016. Pentoxifylline for vascular health: a brief review of the literature. Open Heart. 3(1):e000365
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. 2007. Early human atherosclerosis: accumulation of lipid. ATVB. 27(5):1159–1165.
   Web of Science ®Google Scholar
• Neves KR, Nobre HV, Jr., Leal LK, de Andrade GM, Brito GA, Viana GS. 2015. Pentoxifylline neuroprotective effects are possibly related to its anti-inflammatory and TNF-Alpha inhibitory properties, in the 6-OHDA Model of Parkinson's Disease. Parkinson's Dis. 2015:1.
   Web of Science ®Google Scholar
• Okopień B, Buldak L, Bołdys A. 2017. Fibrates in the management of atherogenic dyslipidemia. Expert Rev Cardiovasc Ther. 15(12):913–921.
   PubMed Web of Science ®Google Scholar
• Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG. 2008. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 283(4):2363–2372.
   PubMed Web of Science ®Google Scholar
• Salhiyyah K, Forster R, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA. 2015. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev. 9:CD005262
   PubMed Web of Science ®Google Scholar
• Sirimarco G, Labreuche J, Bruckert E, Goldstein LB, Fox KM, Rothwell PM, Amarenco P. 2014. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke. 45(5):1429–1436.
   PubMed Web of Science ®Google Scholar
• Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, Devay RM, Liang H, Rashid S, Linton MRae. F, Fazio S. 2016. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc Res. 110(2):268–278.
   PubMed Web of Science ®Google Scholar
• Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada T-A, Fjell CD, Thair SA, et al. 2014. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 6(258):258ra143.
   PubMed Web of Science ®Google Scholar